178 related articles for article (PubMed ID: 10586345)
1. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.
Korte W; Jost C; Cogliatti S; Hess U; Cerny T
Ann Oncol; 1999 Oct; 10(10):1249-50. PubMed ID: 10586345
[No Abstract] [Full Text] [Related]
2. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in CD20 positive multiple myeloma.
Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau JL; Bataille R;
Leukemia; 2007 Apr; 21(4):835-6. PubMed ID: 17268523
[No Abstract] [Full Text] [Related]
4. Rituximab in CD20 positive multiple myeloma.
Bergua JM; Cabrera C; Arteta EG; Prieto J
Leukemia; 2008 May; 22(5):1082-3. PubMed ID: 17972949
[No Abstract] [Full Text] [Related]
5. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
[No Abstract] [Full Text] [Related]
6. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG.
Saikia TK; Menon H; Advani SH
Ann Oncol; 2001 Oct; 12(10):1493-4. PubMed ID: 11762825
[No Abstract] [Full Text] [Related]
7. Reply to 'Rituximab activity in CD20-positive multiple myeloma'.
Gozzetti A; Fabbri A; Lazzi S; Bocchia M; Lauria F
Leukemia; 2008 May; 22(5):1083; author reply 1083-4. PubMed ID: 17972948
[No Abstract] [Full Text] [Related]
8. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma.
Hofer S; Hunziker S; Dirnhofer S; Ludwig C
Br J Haematol; 2003 Aug; 122(4):690-1. PubMed ID: 12899729
[No Abstract] [Full Text] [Related]
9. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
Boye J; Elter T; Engert A
Ann Oncol; 2003 Apr; 14(4):520-35. PubMed ID: 12649096
[TBL] [Abstract][Full Text] [Related]
10. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
Baz R; Fanning S; Kunkel L; Gaballa S; Karam MA; Reed J; Kelly M; Hussein M
Leuk Lymphoma; 2007 Dec; 48(12):2338-44. PubMed ID: 18067008
[TBL] [Abstract][Full Text] [Related]
11. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar O; Becker S; Schilling MK; Maurer CA
Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
[No Abstract] [Full Text] [Related]
12. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
Treon SP; Pilarski LM; Belch AR; Kelliher A; Preffer FI; Shima Y; Mitsiades CS; Mitsiades NS; Szczepek AJ; Ellman L; Harmon D; Grossbard ML; Anderson KC
J Immunother; 2002; 25(1):72-81. PubMed ID: 11924912
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: therapeutic benefit! Vitamin R?
Mo C; Vire B; Wiestner A
Semin Hematol; 2010 Apr; 47(2):105-6. PubMed ID: 20350656
[No Abstract] [Full Text] [Related]
14. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation.
Musto P; Carella AM; Greco MM; Falcone A; Sanpaolo G; Bodenizza C; Cascavilla N; Melillo L; Carella AM
Br J Haematol; 2003 Nov; 123(4):746-7. PubMed ID: 14616983
[No Abstract] [Full Text] [Related]
15. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
[No Abstract] [Full Text] [Related]
16. Long-term response to maintenance treatment with rituximab in CD20(+) multiple myeloma.
Ohno H
Leuk Lymphoma; 2010 Nov; 51(11):2144-6. PubMed ID: 20807088
[No Abstract] [Full Text] [Related]
17. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L
Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626
[No Abstract] [Full Text] [Related]
18. Daratumumab for the Treatment of Multiple Myeloma.
Plesner T; Krejcik J
Front Immunol; 2018; 9():1228. PubMed ID: 29915586
[TBL] [Abstract][Full Text] [Related]
19. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
20. [Loss of CD20 expression following rituximab-combined chemotherapy in CD20-positive and CyclinD1-positive multiple myeloma].
Shiratori S; Kondo T; Kubota K; Wakasa K; Ibata M; Shono Y; Takahata M; Shigematu A; Kato N; Ota S; Tanaka J; Matsuno Y; Asaka M; Imamura M
Rinsho Ketsueki; 2008 Nov; 49(11):1536-40. PubMed ID: 19047784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
